| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802258101014 | 225810101 | CAELYX C/S.SOL.IN 2MG/ML 1VIALX10ML | 313.00 | 317.70 | 370.44 |
For the treatment of Koposi's sarcome connected to AIDS.
Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
LD<sub>50</sub>=21800 ug/kg (rat, subcutaneous)
55 hours
Plasma clearance is in the range 324 to 809 mL/min/m2 and is predominately by metabolism and biliary excretion.
* 324-809 mL/min/m2 * 1088 mL/min/m2 [Men] * 433 mL/min/m2 [Women] * 1540 mL/min/m2 [children greater than 2 years of age receiving administration of 10 to 75 mg/m2 doses] * 813 mL/min/m2 [infants younger than 2 years of age receiving administration of 10 to 75 mg/m2 doses]